诺和诺德在辉瑞匹配其最新报价后,退出了与辉瑞对临床阶段生物技术公司Metsera的竞购战,辉瑞以100亿美元达成交易——远高于其9月的初始报价。这场激烈的竞争始于诺和诺德在10月底的意外出价。CFRA Research的分析师万·努尔哈亚蒂赞扬了诺和诺德退出的决定,称此举避免了过度支付的风险,并展现了资本纪律,尽管其资产负债表较同行更为强劲。然而,她强调诺和诺德仍需加强其后期研发管线,以应对日益...
Source Link诺和诺德在辉瑞匹配其最新报价后,退出了与辉瑞对临床阶段生物技术公司Metsera的竞购战,辉瑞以100亿美元达成交易——远高于其9月的初始报价。这场激烈的竞争始于诺和诺德在10月底的意外出价。CFRA Research的分析师万·努尔哈亚蒂赞扬了诺和诺德退出的决定,称此举避免了过度支付的风险,并展现了资本纪律,尽管其资产负债表较同行更为强劲。然而,她强调诺和诺德仍需加强其后期研发管线,以应对日益...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.